Dr Agarwals Eye Hospital Ltd
₹ 4,922
8.82%
22 Aug
- close price
About
Dr Agarwal's Eye Hospital Ltd is a leading chain of eye hospitals with predominant presence in Tamil Nadu.[1]
Key Points
- Market Cap ₹ 2,314 Cr.
- Current Price ₹ 4,922
- High / Low ₹ 7,300 / 3,500
- Stock P/E 40.0
- Book Value ₹ 446
- Dividend Yield 0.05 %
- ROCE 17.4 %
- ROE 29.8 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 32.3% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 33.3%
Cons
- Stock is trading at 11.0 times its book value
- Company might be capitalizing the interest cost
- Promoters have pledged or encumbered 55.4% of their holding.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
113 | 118 | 137 | 149 | 153 | 170 | 176 | 140 | 201 | 268 | 319 | 397 | 414 | |
102 | 103 | 119 | 126 | 129 | 140 | 129 | 109 | 143 | 192 | 227 | 279 | 290 | |
Operating Profit | 11 | 15 | 18 | 23 | 24 | 30 | 47 | 31 | 59 | 76 | 92 | 118 | 124 |
OPM % | 9% | 13% | 13% | 15% | 16% | 18% | 27% | 22% | 29% | 28% | 29% | 30% | 30% |
3 | 0 | -5 | 1 | 2 | 2 | 3 | 1 | 1 | 2 | 5 | 5 | 5 | |
Interest | 4 | 4 | 5 | 4 | 3 | 4 | 9 | 7 | 7 | 8 | 8 | 13 | 15 |
Depreciation | 6 | 6 | 9 | 9 | 10 | 11 | 21 | 19 | 20 | 20 | 27 | 39 | 40 |
Profit before tax | 4 | 5 | -0 | 11 | 13 | 17 | 20 | 6 | 32 | 49 | 62 | 71 | 75 |
Tax % | 35% | -6% | -104% | 33% | 49% | 32% | 31% | 125% | 25% | 25% | 26% | 23% | |
2 | 6 | 0 | 7 | 7 | 12 | 14 | -1 | 24 | 37 | 46 | 55 | 58 | |
EPS in Rs | 5.17 | 12.13 | 0.09 | 15.62 | 14.43 | 25.36 | 29.11 | -3.06 | 51.28 | 78.55 | 98.64 | 116.28 | 122.98 |
Dividend Payout % | 23% | 10% | 940% | 10% | 8% | 6% | 0% | 0% | 6% | 4% | 3% | 5% |
Compounded Sales Growth | |
---|---|
10 Years: | 13% |
5 Years: | 18% |
3 Years: | 25% |
TTM: | 22% |
Compounded Profit Growth | |
---|---|
10 Years: | 25% |
5 Years: | 32% |
3 Years: | 32% |
TTM: | 18% |
Stock Price CAGR | |
---|---|
10 Years: | 43% |
5 Years: | 80% |
3 Years: | 83% |
1 Year: | 23% |
Return on Equity | |
---|---|
10 Years: | 29% |
5 Years: | 30% |
3 Years: | 33% |
Last Year: | 30% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Reserves | 14 | 19 | 19 | 25 | 30 | 41 | 51 | 50 | 73 | 109 | 152 | 205 |
28 | 27 | 31 | 23 | 18 | 24 | 60 | 68 | 193 | 232 | 268 | 333 | |
20 | 18 | 24 | 20 | 28 | 31 | 24 | 33 | 42 | 44 | 71 | 71 | |
Total Liabilities | 67 | 69 | 79 | 72 | 81 | 100 | 141 | 155 | 314 | 390 | 496 | 613 |
26 | 26 | 34 | 33 | 36 | 55 | 94 | 96 | 214 | 260 | 316 | 393 | |
CWIP | 0 | 0 | 1 | 1 | 3 | 0 | 0 | 0 | 26 | 62 | 97 | 128 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13 |
41 | 43 | 44 | 38 | 42 | 45 | 47 | 60 | 73 | 67 | 83 | 80 | |
Total Assets | 67 | 69 | 79 | 72 | 81 | 100 | 141 | 155 | 314 | 390 | 496 | 613 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
12 | 14 | 17 | 20 | 19 | 25 | 39 | 34 | 57 | 70 | 90 | 94 | |
-11 | -10 | -17 | -8 | -11 | -25 | -17 | -11 | -46 | -71 | -70 | -133 | |
-3 | -5 | -0 | -12 | -8 | 2 | -20 | -8 | -4 | 0 | -14 | 17 | |
Net Cash Flow | -2 | -1 | 0 | 0 | -0 | 2 | 2 | 15 | 7 | -1 | 6 | -22 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 19 | 19 | 24 | 16 | 17 | 19 | 14 | 23 | 16 | 14 | 15 | 13 |
Inventory Days | 96 | 238 | 200 | 123 | 148 | 124 | 132 | 117 | 91 | 73 | 106 | 117 |
Days Payable | 137 | 360 | 371 | 277 | 353 | 292 | 224 | 401 | 410 | 327 | 345 | 263 |
Cash Conversion Cycle | -22 | -103 | -146 | -138 | -189 | -149 | -78 | -260 | -303 | -240 | -224 | -133 |
Working Capital Days | -52 | -31 | -39 | -25 | -39 | -22 | -34 | -70 | -58 | -50 | -63 | -40 |
ROCE % | 17% | 19% | 18% | 29% | 32% | 34% | 30% | 11% | 20% | 19% | 18% | 17% |
Documents
Announcements
- Board Meeting Intimation for Considering The Proposal To Raise Funds By Issuance Of Equity Shares Of The Company To Dr. Agarwal''s Health Care Limited (Promoter Of The Company) By Way Of Preferential Allotment 3m
- Results- Financial Results For June 30, 2025 12 Aug
-
Board Meeting Outcome for For Approval Of The Unaudited Financial Results For The Quarter Ended June 30, 2025
12 Aug - Q1 FY2026 unaudited results: Revenue INR 116.92 Cr, Net Profit INR 17.26 Cr, EPS 36.72.
-
Announcement under Regulation 30 (LODR)-Credit Rating
30 Jul - CRISIL reaffirms A+ rating, revises outlook to Positive on Rs.130 crore bank facilities.
-
Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended June 30, 2025
30 Jul - Board meeting on Aug 12 to approve Q1 FY26 un-audited financial results.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Services Offered
The company's centers offer comprehensive services in the eye-care segment including cataract, glaucoma, laser correction, corner and refractive, retina, squint, etc. [1]